Renalytix PLC Notice of GM and Posting of Circular (0238Z)

TIDMRENX

RNS Number : 0238Z

Renalytix PLC

11 May 2023

Renalytix plc

("Renalytix" or the "Company")

Notice of General Meeting and Posting of Circular

LONDON and SALT LAKE CITY, May 11, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that a circular containing a notice convening a General Meeting to be held at the offices of Harwood Capital LLP, 6 Stratton Street Mayfair, London W1J 8LD at 3 p.m. (BST) on 8 June 2023, has today been posted to the Company's shareholders.

An electronic copy of the circular will shortly be available on the Company's website at www.renalytix.com in accordance with AIM Rule 20.

For further information, please contact:

 
Renalytix plc                                                                               www.renalytix.com 
James McCullough, CEO                                                                         Via Walbrook PR 
 
Stifel (Nominated Adviser, Joint Broker)                                                   Tel: [phone] 
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea 
 
Investec Bank plc (Joint Broker)                                                           Tel: [phone] 
Gary Clarence / Shalin Bhamra 
 
Walbrook PR Limited                                            Tel: [phone] or [e-mail] 
Paul McManus / Lianne Applegarth                                           Mob: [phone] 
 
CapComm Partners 
Peter DeNardo                                                    Tel: [phone] or [e-mail] 
 
 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis(TM) for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGEAFSEFEPDEAA

(END) Dow Jones Newswires

May 11, 2023 02:00 ET (06:00 GMT)